Michael Aregger
Has grant
NIH Stadtman Investigator
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Mapping genetic interactions in patient-derived cancer models to uncover novel therapeutic targets for Renal Cell Carcinomas
Open Date: 2022-10-01
Close Date: 2024-10-01
Grant: Close
Identification of genetic networks required for reprogramming of cancer cells in response to metabolic stress using next-generation CRISPR-Cas9 screens
Open Date: 2016-01-01
Close Date: 2017-06-30
Grant: Close
Systemic analysis of the gene expression reprogramming induced by environmental stress in cancer cells
Open Date: 2014-07-01
Close Date: 2015-12-31
Articles (6)
Year:
2026
Alternative splicing is a pervasive gene regulatory mechanism critical for diversifying the human proteome. To systematically investigate its role in cell fate determination, we develop scCHyMErA-Seq, a scalable CRISPR-based exon deletion screening platform integrated with 10x Genomics single-cell transcriptomic readouts. This tool enables efficient exon deletion while simultaneously capturing Cas9/Cas12a guides and polyadenylated transcripts at single-cell resolution. Applying scCHyMErA-Seq to high-throughput profiling of alternative cassette exons, we identify numerous exons with pronounced regulatory effects on gene expression and cell cycle progression. Analysis of the alternative NRF1 exon-7 demonstrates that its inclusion modulates NRF1’s regulatory function by influencing its recruitment to the promoters of target genes. Importantly, gene expression profiles generated using scCHyMErA-Seq accurately recapitulate findings from traditional, labor-intensive orthogonal methods, while offering enhanced scalability and efficiency. Overall, scCHyMErA-Seq represents a versatile platform for systematically unraveling the functional impact of alternative splicing by directly linking specific splicing variants to transcriptional phenotypes.
Year:
2026
Genetic interaction (GI) networks in model organisms have revealed how combinations of genome variants can impact phenotypes. To advance efforts toward a reference human GI network, we developed the q uantitative G enetic Interaction (qGI) score, a method for precise GI measurement from genome-wide CRISPR-Cas9 screens in different query mutants constructed in a single human cell line. We found surprising prevalent systematic variation unrelated to GIs in CRISPR screen data, including both genomically linked effects and functionally coherent covariation. Leveraging ∼40 control screens in wild-type cells and half a billion differential fitness effect measurements, we developed a pipeline for CRISPR screen data processing and normalization to correct these artifacts and measure accurate, quantitative GIs. We also comprehensively characterized GI reproducibility by characterizing 4 – 5 biological replicates for ∼125,000 unique gene pairs. The qGI framework enables systematic identification of human GIs and provides broadly applicable strategies for analyzing context-specific CRISPR screen data.
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (14)
Maximilian Billmann
Assistant Professor
University Hospital Bonn
Charles Boone
Professor
University of Toronto
Steve Cappell
Principle Investigator
National Cancer Institute
Dae-Kyum Kim
Associate Member
Roswell Park Comprehensive Cancer Center
Jason Moffat
Senior Scientist and Program Head
Hospital for Sick Children
Scott Dixon
Associate Professor
Stanford University
Kevin Lin
University of Minnesota
Chad L Myers
Professor
University of Minnesota
Brenda J Andrews
University of Toronto
Thomas Gonatopoulos-Pournatzis
NIH Stadtman Investigator
National Institutes of Health
Alexendar Perez
University of California, San Francisco
Wen Wang
Researchers, Research Professional 5
University of Minnesota
James Anthony Cornwell
National Institutes of Health
Jolanda van Leeuwen
Associate professor
University of Massachusetts Chan Medical School
Make your next move.
Prepare your application
Review drafts before you send them.